The FDA has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 µg, from Novartis, as monotherapy for the long-term maintenance treatment...
Sunovion Pharma announces that it has entered into an exclusive agreement with Novartis for the US commercialization rights to three...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
The GLOW 3 study investigated the effects of Seebri Breezhaler (NVA237), (glycopyrronium bromide) 50 mcg once-daily from Novartis on exercise...
Novartis announced that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg...
Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for...
The FDA has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder, from Novartis, for the long-term maintenance treatment...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Seebri Breezhaler...
Novartis and Vectura reported one-year data from the pivotal, Phase III GLOW 2 study, confirming that the inhaled long acting...
Results of the first pooled analysis of GLOW1 and GLOW2 data demonstrated that patients with COPD using the Seebri Breezhaler...